Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silver Range Resources: A hidden gem in the mining industry (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline... see more

Recent & Breaking News (PINL:ZLDPF)

Zealand Pharma to attend Deutsche Bank Securities 43rd Annual Health Care Conference, in Boston on May 8, 2018

GlobeNewswire May 2, 2018

Zealand's Annual General Meeting in 2018

GlobeNewswire April 19, 2018

Zealand Pharma will attend the Kempen Life Science Conference on April 18, 2018 in Amsterdam

GlobeNewswire April 12, 2018

Zealand and Roche Diabetes Care enter Phase 3 study collaboration for treatment of congenital hyperinsulinism with dasiglucagon

GlobeNewswire April 11, 2018

Zealand Pharma convenes its Annual General Meeting 2018

GlobeNewswire March 22, 2018

Zealand Pharma to present at the Needham Healthcare Conference, March 27, 2018 in New York

GlobeNewswire March 22, 2018

Zealand Pharma's first Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia successfully meets its primary objective

GlobeNewswire March 20, 2018

Zealand Pharma 2017 full-year results in line with guidance - considerable progress in the clinical portfolio

GlobeNewswire March 7, 2018

Zealand reports royalty revenue for the fourth quarter of 2017

GlobeNewswire February 7, 2018

Zealand Pharma hosts Capital Market Day: Accelerating the late stage pipeline

GlobeNewswire January 25, 2018

Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.

GlobeNewswire January 23, 2018

New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)

GlobeNewswire January 23, 2018

Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018

GlobeNewswire January 19, 2018

Zealand Pharma strengthens its Management by appointing Ivan Møller as SVP, Technical Development & Operations

GlobeNewswire January 19, 2018

Zealand Pharma major shareholder announcement: Wellington Management Group LLP, U.S.

GlobeNewswire January 3, 2018

Zealand Pharma boosts collaboration with Beta Bionics to advance development of its dasiglucagon in the iLetTM

GlobeNewswire December 21, 2017

Zealand Pharma: Invitation to Capital Market Day in New York on 25 January, and event in Copenhagen on 29 January 2018

GlobeNewswire December 21, 2017

Zealand Pharma initiates the pivotal Phase 3 trial with dasiglucagon for the treatment of severe hypoglycemia in diabetes

GlobeNewswire December 7, 2017

Employee elected board member change in Zealand Pharma

GlobeNewswire December 1, 2017

Financial calendar for Zealand Pharma in 2018

GlobeNewswire November 30, 2017